Trial of Point-of-treatment Xpert MTB/RIF Assay

NCT01554384 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1472

Last updated 2013-06-06

No results posted yet for this study

Summary

Xpert MTB/RIF assay is a novel automated molecular tool for the diagnosis of TB. Xpert can detect TB genetic material in sputum samples as well as test for genetic resistance to rifampicin providing results within 2 hours. Xpert received WHO endorsement in December 2010. There is limited data on the impact of Xpert on time-to-treatment and TB-related patient morbidity in primary care clinics. No studies have yet evaluated Xpert performed at the point-of-treatment (POT) i.e. in primary care clinic location. The investigators hypothesize that one sputum GeneXpert MTB/RIF assay performed at the POT will improve time-to-diagnosis, time-to-treatment and TB related patient morbidity for patients with suspected TB presenting to primary level TB clinics in high HIV prevalent settings.

Conditions

Interventions

PROCEDURE

Xpert MTB/RIF assay

Automated nucleic-acid amplification test (fully integrated) test for TB

PROCEDURE

Smear microscopy

Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading

Sponsors & Collaborators

  • Biomedical Research and Training Institute

    collaborator OTHER
  • University of Zimbabwe

    collaborator OTHER
  • University of Zambia

    collaborator OTHER
  • Medical Research Council, South Africa

    collaborator OTHER
  • Mbeya medical research program

    collaborator UNKNOWN
  • McGill University

    collaborator OTHER
  • Radboud University Medical Center

    collaborator OTHER
  • University of Cape Town Lung Institute

    collaborator OTHER
  • University of Cape Town

    lead OTHER

Principal Investigators

  • Keertan Dheda, MD PhD · University of Cape Town

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • South Africa
  • Zambia
  • Zimbabwe

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01554384 on ClinicalTrials.gov